

Financial news for PSDV dated on 2018-04-23: 32 Biggest Movers From Yesterday

Financial news for PSDV dated on 2018-03-29: Benzinga Pro's 5 Stocks To Watch Today

Financial news for PSDV dated on 2018-03-28: pSivida Shares Up 24.3% Postmarket After Co. Announced Plan To Acquire Icon Bioscience For \$60.5M And Rebrand As EyePoint Pharmaceuticals

Financial news for PSDV dated on 2018-03-28: pSivida Shares Resume Trade, Up 39.3%

Financial news for PSDV dated on 2018-03-28: pSivida Reports Purchase Of Icon Bioscience For Up To ~\$60.5M

Financial news for PSDV dated on 2018-03-19: pSivida Shares Up 7%; Co. Reported FDA Acceptance Of Filing For NDA For Durasert 3-Year Treatment For Posterior Segment Uveitis

Financial news for PSDV dated on 2018-02-07: pSivida Reports Second Phase 3 Study For Durasert Showed 'Highly Significant Difference Between Durasert and Sham in Prevention of Uveitis Recurrence at 12 Months'

Financial news for PSDV dated on 2018-02-07: pSivida Reports Q2 EPS \$(0.13) vs \$(0.15) Est., Sales \$933K vs \$510K Est.

Financial news for PSDV dated on 2018-01-08: pSivida Earlier Announced Submission Of NDA For Durasert

Financial news for PSDV dated on 2018-01-04: pSivida Granted Waiver by the FDA for New Drug Application Filing Fee

Financial news for PSDV dated on 2017-12-14: pSivida, HSS Report Results Of Phase I Safety, Exploratory Efficacy Pilot Study: 'Subjects experienced an average 3.8 point reduction in average weekly pain by week 4 that did not diminish over the 24 week period'

Financial news for PSDV dated on 2017-12-04: Spike In pSivida Spikes To High Of \$1.38 On Rumor That B. Riley Initiated Coverage Of The Company With A Buy Rating And \$5 PT

Financial news for PSDV dated on 2017-11-08: Laidlaw & Co. Initiates Coverage On pSivida with Buy Rating, Announces \$5.00 Price Target

Financial news for PSDV dated on 2017-11-07: pSivida Q1 EPS \$(0.15) vs \$(0.15) Est., Sales \$385K vs \$640K Est.

Financial news for PSDV dated on 2017-10-10: pSivida Reports Strategic Collaboration With Nicox For Development Of Sustained Release Drug To Lower Intraocular Pressure In Patients With Glaucoma

Financial news for PSDV dated on 2017-09-26: pSivida Partners with a 'Major Global Pharmaceutical Company' to Develop Glaucoma Drugs, Receives \$750K Upfront Payment

Financial news for PSDV dated on 2017-09-11: pSivida Reports Q4 EPS \$(0.16) vs \$(0.15) Est., Sales \$701K vs \$470K Est.

Financial news for PSDV dated on 2017-09-11: Earnings Scheduled For September 11, 2017

Financial news for PSDV dated on 2017-07-10: UPDATE: pSivida Says Sales-Based Royalty Payments To Co. Will Start At 2%, Increases To 6% Upon Earliest Of 3 Events, Will Increase To 8% Based On ILUVIEN Sales In Excess Of \$75M In Any Calendar Year

Financial news for PSDV dated on 2017-07-10: UPDATE: pSivida Offers Key Terms Of Restructured Global Licensing Deal For ILUVIEN: Co. Grants Alimera Rights To Durasert In EMEA Under ILUVIEN Trademark In Exchange For Tiered Sales-Based Royalty Payments

Financial news for PSDV dated on 2017-07-10: pSivida Reports Out-Licensed EMEA Rights For Durasert 3-Year Treatment For Posterior Segment Uveitis While Retaining US Commercial Rights

Financial news for PSDV dated on 2017-06-27: Companies Holding Shareholder Meetings Today Include Autohome, Gamestop, Mastercard, Kyocera, Intercept Pharma, PNC Financial, pSivida, ReWalk Robotics, RH, SITO Mobile, and Synergy Pharmaceuticals

Financial news for PSDV dated on 2017-06-22: pSivida Submits Marketing Authorization Application for Approval of Durasert in the European Union

Financial news for PSDV dated on 2017-06-15: 12 Biggest Mid-Day Gainers For Thursday

Financial news for PSDV dated on 2017-06-15: 22 Stocks Moving In Thursday's Pre-

Market Session

Financial news for PSDV dated on 2017-06-14: pSivida Corp.CEO Nancy Lurker Buys \$6,700 @ Avg Price: \$1.76 -Form4

Financial news for PSDV dated on 2017-06-13: 12 Biggest Mid-Day Losers For Tuesday

Financial news for PSDV dated on 2017-06-13: Mid-Day Market Update: Cavco Rises After Q4 Results; CEL-SCI Shares Plunge

Financial news for PSDV dated on 2017-06-13: Mid-Morning Market Update: Markets Open Higher; John Wiley Reports Strong Q4 Results

Financial news for PSDV dated on 2017-06-13: 25 Stocks Moving In Tuesday's Pre-Market Session

Financial news for PSDV dated on 2017-06-13: A Peek Into The Markets: U.S. Stock Futures Rise Ahead Of Fed Meeting

Financial news for PSDV dated on 2017-06-13: pSivida Says Phase 3 Trial for Durasert Met Primary Endpoint

Financial news for PSDV dated on 2017-05-30: 15 Biggest Mid-Day Gainers For Tuesday

Financial news for PSDV dated on 2017-05-30: 22 Stocks Moving In Tuesday's Pre-Market Session

Financial news for PSDV dated on 2017-05-30: Rodman & Renshaw Initiates Coverage On pSivida with Buy Rating, Announces \$8.00 Price Target

Financial news for PSDV dated on 2017-05-26: Amended 13D from Pfizer on pSivida Shows 4.7% Stake

Financial news for PSDV dated on 2017-05-04: pSivida Reports Q3 EPS \$(0.15) In-line With Est., Sales \$590K vs \$420K Est.

Financial news for PSDV dated on 2017-04-07: 13G from Rosalind Advisors on pSivida Shows New 6.2% Stake

Financial news for PSDV dated on 2017-02-07: pSivida Reports Q2 EPS Break-Even vs \$(0.18) Est, Revenue \$6M vs \$300K Est

Financial news for PSDV dated on 2016-12-02: Stocks Hitting 52-Week Lows

Financial news for PSDV dated on 2016-11-07: pSivida Reports Q1 Loss/Share \$0.21 vs Est Loss/Share \$0.19, Rev \$277K vs \$330K Est

Financial news for PSDV dated on 2016-11-07: pSivida Provides Clinical Update

Financial news for PSDV dated on 2016-10-04: Phase 3 trial of Medidur in Posterior Segment Uveitis Meets Enrollment Target, EU Filing Remains On Track For Q1 2017 Filing

Financial news for PSDV dated on 2016-09-22: Mid-Afternoon Market Update: Crude Oil Up 2.2%; OMNOVA Shares Drop On Earnings Miss

Financial news for PSDV dated on 2016-09-15: pSivida Announces Nancy Lurker President and CEO

Financial news for PSDV dated on 2016-09-12: pSivida Reports Q4 EPS \$(0.19) vs \$(0.13) Est., Sales \$304K vs \$1.43M Est.

Financial news for PSDV dated on 2016-09-12: Earnings Scheduled For September 12, 2016

Financial news for PSDV dated on 2016-09-02: Mid-Morning Market Update: Markets Open Higher; Lululemon Sales Miss Views

Financial news for PSDV dated on 2016-08-09: pSivida Reports Utilization Study of New Medidur Inserter Met Primary Endpoint, Results Will Form Part of Planned Applications for Marketing Approvals in EU, US

Financial news for PSDV dated on 2016-08-03: pSivida Names Dr. Dario Paggiarino Chief Medical Officer

Financial news for PSDV dated on 2016-07-27: pSivida's Medidur Maintains Same High Statistical Significance in Primary Endpoint through 12 Months in First Phase 3 Trial (p Less Than 0.00000001)

Financial news for PSDV dated on 2016-07-20: pSivida's Tethadur Data Released Company Says It Provides Prolonged Sustained Release of Avastin With High Drug Efficacy

Financial news for PSDV dated on 2016-07-15: pSivida Reports Plan to Consolidate All R&D in Current US Facility

Financial news for PSDV dated on 2016-07-14: Investigator-Sponsored Phase 2 Study Results Show pSivida's Medidur Fully Controlled Uveitis for Two Years with No Recurrence of Disease While Visual Acuity Continued to Improve

Financial news for PSDV dated on 2016-05-05: pSivida Corp Reports Q3 EPS \$(0.15) Vs Est \$(0.20), Sales \$324K Vs Est \$500K

Financial news for PSDV dated on 2016-05-02: pSivida Reports Orphan Drug Designation in Europe for Medidur for Posterior Uveitis

Financial news for PSDV dated on 2016-04-25: Mid-Day Market Update: Tribune Publishing Jumps Following Gannett's Takeover Proposal; TrovaGene Shares Drop

Financial news for PSDV dated on 2016-04-25: Mid-Morning Market Update: Markets Open Lower; Xerox Profit Misses Views

Financial news for PSDV dated on 2016-04-21: Watch Small Cap Biotech Shares On Alimera Halts, Companies up 5% Or Higher On The Day Include Inotek Pharmaceuticals, Avalanche Biotech, Opthothotech

Financial news for PSDV dated on 2016-04-21: pSivida Shares Trading Up \$0.33 To \$3.45/Share up 11% On The Day, Possibly In Sympathy With Alimera Sciences

Financial news for PSDV dated on 2016-04-05: Mid-Afternoon Market Update: Dow Falls Over 100 Points; Valeant Pharmaceuticals Shares Spike Higher

Financial news for PSDV dated on 2016-03-15: pSivida Offers Added Favorable Six-Month Safety Results for Medidur for PU

Financial news for PSDV dated on 2016-02-08: pSivida Reports Q2 EPS \$(0.18) vs \$(0.15) Est., Sales \$526K vs \$980K Est.

Financial news for PSDV dated on 2016-01-07: pSivida To Resume Trade At 8:50am

Financial news for PSDV dated on 2016-01-07: pSivida Prices \$16M Offering Of 4M Shares At \$4/Share

Financial news for PSDV dated on 2016-01-07: UPDATE: pSivida Halted on ASX at Request of Co; Triggered Halt on Nasdaq

Financial news for PSDV dated on 2016-01-06: pSivida Shares Halted on Regulatory Concern

Financial news for PSDV dated on 2016-01-06: pSivida Reports Offering of Common Shares, No Amount disclosed

Financial news for PSDV dated on 2015-12-29: Benzinga's Top #PreMarket Losers

Financial news for PSDV dated on 2015-12-28: Mid-Afternoon Market Update: Chimerix Slides Following Phase 3 Trial Failure; InterDigital Shares Rise

Financial news for PSDV dated on 2015-12-28: Mid-Day Market Update: Crude Oil Down Over 3%; Rovi Shares Jump Following Renewal Of Agreement With Sony

Financial news for PSDV dated on 2015-12-28: Mid-Morning Market Update: Markets Open Lower; Bridgestone Increases Offer Price For Pep Boys

Financial news for PSDV dated on 2015-12-28: Benzinga's Top #PreMarket Gainers

Financial news for PSDV dated on 2015-12-28: pSivida Plans Medidur EU Marketing Approval Application Based on Single Phase 3 Clinical Trial

Financial news for PSDV dated on 2015-12-22: Mid-Afternoon Market Update: Dow Jumps Over 150 Points; Steelcase Shares Dip Following Weak Results

Financial news for PSDV dated on 2015-12-22: Mid-Day Market Update: Cintas Gains On Earnings Beat; NetApp Shares Slide

Financial news for PSDV dated on 2015-12-22: Why pSivida And Alexza Are Skyrocketing

Financial news for PSDV dated on 2015-12-22: Mid-Morning Market Update: Markets Edge Higher; ConAgra Posts Mixed Q2 Results

Financial news for PSDV dated on 2015-12-22: Stocks Hitting 52-Week Highs

Financial news for PSDV dated on 2015-12-22: Benzinga's Top #PreMarket Gainers

Financial news for PSDV dated on 2015-12-22: pSivida Reports Medidur Has Met Primary Efficacy Endpoint in Phase 3 Trial

Financial news for PSDV dated on 2015-12-08: Option Alert: PSDV Jan16 5.0 Calls Sweep: 1525 @ ASK \$0.20: 1593 traded vs 1465 OI: \$3.83 Ref

Financial news for PSDV dated on 2015-11-19: S-3 from pSivida Shows Registration for \$75M Mixed Securities Shelf Offering

Financial news for PSDV dated on 2015-10-15: Benzinga's Top Initiations

Financial news for PSDV dated on 2015-10-15: FBR Capital Initiates Coverage on pSivida at Outperform, Announces \$6.00 PT

Financial news for PSDV dated on 2015-09-28: UPDATE: pSivida Says Top-Line Data from First Trial Expected Dec. '15

Financial news for PSDV dated on 2015-09-28: pSivida Reports NDA for Medidur Now Planned Using Six Month Efficacy Data from Phase III Trials, Says FDA Concurs

Financial news for PSDV dated on 2015-09-09: pSivida Offers Update on Trials

Financial news for PSDV dated on 2015-09-09: pSivida Reports Q4 Sales \$409K vs \$620K Est., Loss of \$0.17/Share vs Loss of \$0.14/Share Est.

Financial news for PSDV dated on 2015-07-13: pSivida Reports Top Line Results from Phase II Study of Medidur for Uveitis: Showed Statistically Significant Reduction in Recurrence

Financial news for PSDV dated on 2015-07-07: pSivida Announces Top-Line Results from Investigator-Sponsored Phase II Study of Medidur for Uveitis to Be Reported Next Week

Financial news for PSDV dated on 2015-05-19: pSivida Reports Positive IOP Safety Data in Phase III Trial of Medidur(tm) for Posterior Uveitis

Financial news for PSDV dated on 2015-05-12: pSivida Announces Two Tech Evaluation Deals with Leading Global Pharma Co.

Financial news for PSDV dated on 2015-05-08: pSivida Reports Q3 Loss \$0.17 Vs Est Loss \$0.13, Sales \$328K Vs Est \$600K

Financial news for PSDV dated on 2015-04-14: pSivida Announces ILUVIEN for DME Approved in Poland

Financial news for PSDV dated on 2015-03-26: pSivida Corp. Completes Targeted Enrollment of Phase III Trial of Medidur for Posterior Uveitis

Financial news for PSDV dated on 2015-02-17: pSivida To Begin Shipping ILUVIEN To U.S on Feb. 23

Financial news for PSDV dated on 2015-02-05: pSivida Corp. Reports Second Quarter EPS of \$(0.14)

Financial news for PSDV dated on 2014-12-01: pSivida Corp. Reports ILUVIEN Has Been Granted Marketing Authorization In The Netherlands

Financial news for PSDV dated on 2014-11-17: pSivida Says ILUVIEN Granted Marketing Authorization In Ireland

Financial news for PSDV dated on 2014-11-07: pSivida Corp. Reports Q1 EPS of \$0.67; Revenue of \$25.30M

Financial news for PSDV dated on 2014-10-27: US Stock Futures Down Ahead Of Economic Data

Financial news for PSDV dated on 2014-10-27: pSivida Corp. Receives \$25M Milestone Payment

Financial news for PSDV dated on 2014-09-29: Alimera Sciences Inc Extends Gains On FDA News

Financial news for PSDV dated on 2014-09-29: Morning Market Movers

Financial news for PSDV dated on 2014-09-26: Shares of Alimera, pSivida Resume Trade; Alimera Now Up 11%, pSivida Now Up 13%

Financial news for PSDV dated on 2014-09-26: Shares of Alimera Sciences, pSivida to Resume Trade at 4:45 p.m. EDT

Financial news for PSDV dated on 2014-09-26: UPDATE: pSivida Confirms FDA Approval for ILUVIEN, Will Earn \$25M Milestone

Financial news for PSDV dated on 2014-09-26: pSivida Confirms FDA Approval for ILUVIEN, Will Earn \$25M Milestone

Financial news for PSDV dated on 2014-09-26: Alimera, pSivida Have Won FDA Approval for Iluvien in DME

Financial news for PSDV dated on 2014-09-26: pSivida Halted: Pending News

Financial news for PSDV dated on 2014-09-09: pSivida Corp. Reports Q4 EPS of \$(0.14) vs \$(0.15) Est; Revenue of \$292.0K vs \$550.0K Est

Financial news for PSDV dated on 2014-09-03: pSivida Corp. Receives Marketing Authorization For ILUVIEN

Financial news for PSDV dated on 2014-07-28: pSivida Announces ILUVIEN Marketing Authorization in Norway and Reimbursement Approval in Portugal

Financial news for PSDV dated on 2014-06-30: pSivida Corp. Reports Positive Regulatory Outcome For ILUVIEN; Moves To National Phase For Marketing Authorizations In 10 More EU Countries

Financial news for PSDV dated on 2014-06-23: pSivida Corp. Reports Marketing Authorization in Italy for Iluvien

Financial news for PSDV dated on 2014-06-23: pSivida Announces Iluvien Can Now Be Marketed in Italy

Financial news for PSDV dated on 2014-05-13: pSivida Corp. Reports Q1 EPS of \$(0.08) vs \$(0.15) Est; Revenue of \$2.0M vs \$550.0K Est

Financial news for PSDV dated on 2014-05-05: UPDATE: pSivida Issues Presentation of Preclinical Data Showing Sustained Release of Avastin Using Tethadur

Financial news for PSDV dated on 2014-05-05: pSivida Issues Presentation of Preclinical Data Showing Sustained Release of Avastin Using Tethadur

Financial news for PSDV dated on 2014-05-05: UPDATE: MLV & Co Initiates Coverage On pSivida On Multiple Positive Factors

Financial news for PSDV dated on 2014-05-05: Benzinga's Top Initiations

Financial news for PSDV dated on 2014-05-05: McNicoll Lewis Vlak Initiates Coverage on pSivida Corp. at Buy, Announces \$6.00 PT

Financial news for PSDV dated on 2014-04-28: pSivida Reports Australia/New Zealand Distribution Agreement for ILUVIEN

Financial news for PSDV dated on 2014-04-14: US Stock Futures Flat; Citigroup Earnings In Focus

Financial news for PSDV dated on 2014-04-14: pSivida Announces September 26, 2014 PDUFA Date for ILUVIEN

Financial news for PSDV dated on 2014-03-27: pSivida Announces Resubmission of NDA for ILUVIEN

Financial news for PSDV dated on 2014-03-13: pSivida Announces \$7M Investment By RA Capital

Financial news for PSDV dated on 2014-02-10: pSivida Announces Iluvien for DME Accepted by National Health Service Scotland

Financial news for PSDV dated on 2014-01-13: pSivida Reports First Orders for Iluven Shipped to UK for NHS Hospitals

Financial news for PSDV dated on 2013-12-19: Morning Market Movers

Financial news for PSDV dated on 2013-12-19: Ladenburg Thalmann Lifts Target on pSivida from \$2.75 to \$6, Maintains Buy

Financial news for PSDV dated on 2013-12-19: Benzinga's Top #PreMarket Gainers

Financial news for PSDV dated on 2013-12-18: UPDATE: Alimera Shares Rise 65% After Hours as Co Enters Labeling Discussions with FDA on ILUVIEN

Financial news for PSDV dated on 2013-12-18: pSivida Corp. Reports FDA Labeling Discussions for ILUVIEN(r) for DME; Advisory Committee Meeting No Longer Necessary

Financial news for PSDV dated on 2013-12-18: pSivida Announces FDA Labeling Talks for Iluvien for DME, Says Panel Meeting No Longer Necessary

Financial news for PSDV dated on 2013-12-02: Psivida Announces Iluvien Will Be Funded by UK's NHS

Financial news for PSDV dated on 2013-11-12: pSivida Corp. Reports Q1 EPS of \$(0.14) vs \$(0.13) Est; Revenue of \$597.0K vs \$430.0K Est

Financial news for PSDV dated on 2013-10-18: UPDATE: Alimera Falls 38%, pSivida Down 47% on FDA CRL for ILUVIEN

Financial news for PSDV dated on 2013-10-18: US Stock Futures Up Ahead Of Earnings

Financial news for PSDV dated on 2013-10-18: pSivida Receives CRL from FDA for ILUVIEN

Financial news for PSDV dated on 2013-10-17: Another Leg Lower in pSivida, Alimera Shares as Traders Await Results of PDUFA

Financial news for PSDV dated on 2013-10-07: Northland Securities Initiates Coverage on pSivida Corp. with Outperform

Financial news for PSDV dated on 2013-09-30: pSivida Announces UK's NICE Recommends ILUVIEN for Chronic Diabetic Macular Edema in Pseudophakic Eyes

Financial news for PSDV dated on 2013-09-25: pSivida Corp. Reports Q4 EPS of \$(0.17) vs \$(0.12) Est; Revenue of \$492.0K vs \$650.0K Est

Financial news for PSDV dated on 2013-07-24: pSivida Announces France's Transparency Commission Issues Positive Opinion for Reimbursement of ILUVIEN

Financial news for PSDV dated on 2013-07-11: pSivida Corp. Announces UK's NICE Says Yes to ILUVIEN(r) in Some Patients with Diabetic Macular Edema in New Draft Guidance

Financial news for PSDV dated on 2013-07-01: pSivida Announces Initiation of Phase III Clinical Trial in Posterior Uveitis

Financial news for PSDV dated on 2013-05-29: pSivida Announces Tech Evaluation Agreement With Leading Global Pharmaceutical Company

Financial news for PSDV dated on 2013-05-13: pSivida Corp. Reports Q3 EPS of \$(0.12) vs \$(0.13) Est; Revenue of \$513.0K vs \$650.0K Est

Financial news for PSDV dated on 2013-05-07: pSivida Announces Commercial Launch of ILUVIEN in Germany with First Patient Treated

Financial news for PSDV dated on 2013-05-01: pSivida Announces New ILUVIEN(r) PDUFA Date of October 17, 2013

Financial news for PSDV dated on 2013-04-29: pSivida Says ILUVIEN Available in UK

Financial news for PSDV dated on 2013-04-10: Ladenburg Thalmann Upgrades pSivida Corp. to Buy, Announces \$4.00 PT

Financial news for PSDV dated on 2013-04-04: pSivida Reports Tech Evaluation Deal with Leading Global Pharma Company

Financial news for PSDV dated on 2013-04-01: pSivida Announces NDA Resubmission for ILUVIEN to FDA

Financial news for PSDV dated on 2013-03-22: pSivida Issues Update on ILUVIEN for Planned Resubmission to FDA, European Launch

Financial news for PSDV dated on 2013-02-24: Benzinga's Small Cap Movers for Friday February 22, 2013

Financial news for PSDV dated on 2013-02-22: pSivida Spokesperson Says No Company-Issued News to Account for Today's Move, Shares Currently Up 35%

Financial news for PSDV dated on 2013-02-06: pSivida Corp. Reports Q2 EPS of \$(0.11) vs \$(0.13) Est; Revenue of \$585.0K vs \$600.0K Est

Financial news for PSDV dated on 2013-01-23: Psivida Says NICE Guidance Suggests Iluvien Not Cost Effective

Financial news for PSDV dated on 2013-01-23: pSivida Says DME Deemed Iluvien Not Cost Effective

Financial news for PSDV dated on 2013-01-17: Spain Grants pSivida's ILUVIEN Marketing Approval for Chronic DME Treatment

Financial news for PSDV dated on 2012-12-19: pSivida Files \$30M Mixed Securities Shelf

Financial news for PSDV dated on 2012-11-08: pSivida Reports Q1 EPS \$-0.11 vs \$-0.10 Est; Revenues \$553K vs \$650.00K Est

Financial news for PSDV dated on 2012-09-24: pSivida Reports Q4 EPS \$-0.11 May Not Compare to \$-0.19 Est; Revenues \$700K May Not Compare to \$380.00K Est

Financial news for PSDV dated on 2012-08-01: pSivida Corp. Reports Alimera's Intention to Resubmit Application to FDA for ILUVIEN(r) in DME Using Data from Completed Trials

Financial news for PSDV dated on 2012-07-30: pSivida Corp. Announces Tech Evaluation Agreement for Tethadur(tm) Protein/Antibody Delivery System with Leading Biopharmaceutical Company

Financial news for PSDV dated on 2012-07-29: Benzinga's Microcap Movers for Friday July 27, 2012

Financial news for PSDV dated on 2012-07-19: Benzinga's Microcap Movers for Thursday July 19, 2012

Financial news for PSDV dated on 2012-07-19: pSivida Corp. Receives FDA Clearance for Pivotal Trials for Injectable Sustained-Release Micro-Insert to Treat Uveitis

Financial news for PSDV dated on 2012-07-18: pSivida's Partner Alimera Sciences Announces an Agreement to Raise Capital to Fund the Development and Commercialization of ILUVIEN(r)

Financial news for PSDV dated on 2012-06-06: pSivida Corp. Announces Issuance of US Patent for Insertor to Be Used in Planned Phase III Uveitis Trials

Financial news for PSDV dated on 2012-05-17: pSivida Corp. Announces Expiration of 2.7 Million Warrants

Financial news for PSDV dated on 2012-04-24: pSivida Corp. Announces ILUVIEN Receives Marketing Authorization in Austria for the Treatment of Chronic Diabetic Macular Edema

Financial news for PSDV dated on 2012-03-13: pSivida Announces Second Tech Evaluation Agreement with its BioErodible Durasert Technology

Financial news for PSDV dated on 2012-02-28: pSivida Corp. Announces Positive Outcome to European Decentralized Procedure for Approval of ILUVIEN for the Treatment of Chronic Diabetic Macular Edema

Financial news for PSDV dated on 2012-02-27: Market Movers

Financial news for PSDV dated on 2012-02-26: Benzinga's Microcap Movers for Friday February 24, 2012

Financial news for PSDV dated on 2011-11-11: pSivida Corp Halted for Circuit Breaker

Financial news for PSDV dated on 2011-11-11: pSivida Corp Resumes Trading

Financial news for PSDV dated on 2011-11-11: PREVIEW: pSivida to Resume Trading at 12:50pm

Financial news for PSDV dated on 2011-11-11: pSivida Reports Receipt by Alimera Sciences of Complete Response Letter from FDA for ILUVIEN(r) for DME

Financial news for PSDV dated on 2011-11-11: pSivida Halted; Pending News

Financial news for PSDV dated on 2011-08-24: Hearing Positive Chatter in Psivida Corp

Financial news for PSDV dated on 2011-06-14: pSivida Announces Phase I/II Clinical Study Evaluating Bioerodible, Sustained Release Latanoprost Device in Ocular Hypertension and Glaucoma

Financial news for PSDV dated on 2011-06-14: pSivida and Pfizer Amend Agreement to Focus Solely on Development of Sustained-Release Implant to Deliver Latanoprost

Financial news for PSDV dated on 2011-06-01: Alimera Sciences Confirms ILUVIEN NDA Resubmission Has Been Accepted by the FDA

Financial news for PSDV dated on 2011-05-31: Positive Rumors About Psivida Corp. Circulate (PSDV)

Financial news for PSDV dated on 2011-05-13: pSivida Announces Resubmission of New Drug Application for ILUVIEN

Financial news for PSDV dated on 2011-05-03: pSivida Announces New Safety and Efficacy Data from Phase 3 Study of ILUVIEN(r) in Diabetic Macular Edema (PSDV)

Financial news for PSDV dated on 2011-02-09: pSivida Corp. Reports Results for the Second Quarter Ended December 31, 2010: Net Loss of \$0.15 Per Share

Financial news for PSDV dated on 2011-02-03: pSivida Announces Positive Results from the 36 Month Readout of Completed Phase 3 FAME

Financial news for PSDV dated on 2010-12-27: FDA Rejection Sends pSivida Shares Down 20.1% (PSDV)

Financial news for PSDV dated on 2010-12-27: Afternoon Market Update

Financial news for PSDV dated on 2010-12-27: Options Brief: pSivida Corp. (PSDV)

Financial news for PSDV dated on 2010-12-27: Benzinga's Top Pre-Market NASDAQ Losers (PSDV, TSLA, MGIC, NFLX)

Financial news for PSDV dated on 2010-11-05: pSivida Corp. Reports First Quarter EPS of \$(0.17)

Financial news for PSDV dated on 2010-09-23: Benzinga's Top Pre-Market NASDAQ Gainers (BBBY, PSDV, NVDA, AKAM)

Financial news for PSDV dated on 2010-09-22: pSivida Corp. Reports Fourth Quarter and Fiscal Year 2010 Financial Results

Financial news for PSDV dated on 2009-12-23: Benzinga's Top Pre- Market Gainers (TIBX, PSDV, ACHN, FINL, SNDK, BLDP)